Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Merrill

Showing results (241-250 of 414) with videos related to

Pageof 42
Sort By:
The New England Journal of Medicine|November 25, 2005
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler, Mary Anne Dooley, Cynthia Aranow, et al.
Arthritis and Rheumatism|March 13, 2003
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndromeSudha Visvanathan, Jamie K Scott, Kwan-Ki Hwang, et al.
Annals of the Rheumatic Diseases|August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyJ T Merrill, R F van Vollenhoven, J P Buyon, et al.
Arthritis Care & Research|June 20, 2014
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritisAlan Kivitz, Ewa Olech, Michael Borofsky, et al.
Lupus|August 1, 2007
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosusJ A James, X R Kim-Howard, B F Bruner, et al.
Arthritis and Rheumatism|December 1, 2011
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levelsLauren L Ritterhouse, Sherry R Crowe, Timothy B Niewold, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis Care & Research|May 9, 2017
Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus ErythematosusElianna T Kaplowitz, Sancia Ferguson, Marta Guerra, et al.
Arthritis Care & Research|October 7, 2020
Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical StudiesJessica N Williams, Maria Dall'Era, S Sam Lim, et al.
Pageof 42

Showing results (241-250 of 414) with videos related to

Sort By:
Pageof 42
The New England Journal of Medicine|November 25, 2005
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler, Mary Anne Dooley, Cynthia Aranow, et al.
Arthritis and Rheumatism|March 13, 2003
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndromeSudha Visvanathan, Jamie K Scott, Kwan-Ki Hwang, et al.
Annals of the Rheumatic Diseases|August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyJ T Merrill, R F van Vollenhoven, J P Buyon, et al.
Arthritis Care & Research|June 20, 2014
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritisAlan Kivitz, Ewa Olech, Michael Borofsky, et al.
Lupus|August 1, 2007
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosusJ A James, X R Kim-Howard, B F Bruner, et al.
Arthritis and Rheumatism|December 1, 2011
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levelsLauren L Ritterhouse, Sherry R Crowe, Timothy B Niewold, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis Care & Research|May 9, 2017
Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus ErythematosusElianna T Kaplowitz, Sancia Ferguson, Marta Guerra, et al.
Arthritis Care & Research|October 7, 2020
Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical StudiesJessica N Williams, Maria Dall'Era, S Sam Lim, et al.
Pageof 42